Stockreport

Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification

Repare Therapeutics Inc. - Common Shares  (RPTX) 
PDF Data show PKMYT1 inhibition is a promising therapeutic target in CCNE1-amplified cancersRP-6306, a first-in-class, oral PKMYT1 inhibitor, is currently being evaluated in [Read more]